Cambridge Investment Research Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $644K | Buy |
127,249
+10,129
| +9% | +$51.3K | ﹤0.01% | 2318 |
|
|
2025
Q1 | $620K | Buy |
117,120
+29,136
| +33% | +$154K | ﹤0.01% | 2243 |
|
|
2024
Q4 | $595K | Buy |
87,984
+8,401
| +11% | +$56.8K | ﹤0.01% | 2277 |
|
|
2024
Q3 | $524K | Buy |
79,583
+2,615
| +3% | +$17.2K | ﹤0.01% | 2374 |
|
|
2024
Q2 | $577K | Buy |
76,968
+6,858
| +10% | +$51.4K | ﹤0.01% | 2182 |
|
|
2024
Q1 | $699K | Buy |
70,110
+6,114
| +10% | +$61K | ﹤0.01% | 1993 |
|
|
2023
Q4 | $631K | Buy |
63,996
+4,157
| +7% | +$41K | ﹤0.01% | 2002 |
|
|
2023
Q3 | $458K | Buy |
+59,839
| New | +$458K | ﹤0.01% | 2153 |
|